SUSRF (Surgical Science Sweden AB) YoY EBITDA Growth: 245.65% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SUSRF Surgical Science Sweden AB SUSRF
84 GF Score
Price $5.00
GF Value $15.82
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Surgical Science Sweden AB YoY EBITDA Growth?

Surgical Science Sweden AB SUSRF 84 YoY EBITDA Growth is 245.65% as of Jun. 2026. GuruFocus rates SUSRF with a GF Score™ of 84/100 and a GF Value™ of $15.82 (Significantly Undervalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Surgical Science Sweden AB's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 245.65%.

Surgical Science Sweden AB's EBITDA per Share for the three months ended in Jun. 2026 was $0.07.

Surgical Science Sweden AB YoY EBITDA Growth Related Terms

Surgical Science Sweden AB YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Surgical Science Sweden AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Surgical Science Sweden AB YoY EBITDA Growth Chart

Surgical Science Sweden AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.00 91.47 25.71 -35.59 0.00

Surgical Science Sweden AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -174.19 -35.23 21.43 4.35 245.65
SUSRF
84GF Score
Surgical Science Sweden AB SUSRF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Surgical Science Sweden AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Surgical Science Sweden AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.4-0.4)/ | 0.4 |
=0.00 %

Surgical Science Sweden AB's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.067--0.046)/ | -0.046 |
=245.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 245.65% mean?
Surgical Science Sweden AB (SUSRF) has a YoY EBITDA Growth of 245.65% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Surgical Science Sweden AB and its competitors.
Is Surgical Science Sweden AB's YoY EBITDA Growth too high?
Surgical Science Sweden AB's current YoY EBITDA Growth is 245.65%. Overall, Surgical Science Sweden AB has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's YoY EBITDA Growth compare to VEEV and BTSG?
Surgical Science Sweden AB's YoY EBITDA Growth of 245.65% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Surgical Science Sweden AB and its competitors. Surgical Science Sweden AB's current YoY EBITDA Growth is 245.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $15.82, compared to a current price of $5.00 — trading 68.4% below its estimated fair value. The current YoY EBITDA Growth is 245.65%. Surgical Science Sweden AB's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current YoY EBITDA Growth is 245.65% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?

Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued. The current stock price of $5.00 is trading 68.4% below its estimated GF Value™ of $15.82. GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.

Key valuation signals for SUSRF:

  • YoY EBITDA Growth: 245.65%
  • GF Value™: $15.82 vs. price of $5.00 (68.4% below fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Surgical Science Sweden AB Business Description

Other Exchanges SUS:Sweden4P41:Germany
Address Drakegatan 7A, Gothenburg, SWE, SE-412 50
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
84GF Score

Get the complete analysis for SUSRF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.00
Price
$15.82
GF Value